What is HC Wainwright’s Estimate for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of FibroGen in a report issued on Tuesday, March 18th. HC Wainwright analyst M. Keller anticipates that the biopharmaceutical company will earn $0.04 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.69) EPS.

Separately, StockNews.com assumed coverage on FibroGen in a research note on Friday, March 14th. They set a “hold” rating for the company.

FibroGen Trading Down 5.9 %

Shares of FGEN opened at $0.34 on Thursday. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80. The firm has a market capitalization of $33.91 million, a P/E ratio of -0.27 and a beta of 0.82. The stock’s fifty day simple moving average is $0.49 and its 200 day simple moving average is $0.43.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $24.91 million.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of FGEN. Mackenzie Financial Corp raised its stake in shares of FibroGen by 416.6% in the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock valued at $290,000 after acquiring an additional 441,083 shares during the period. Velan Capital Investment Management LP acquired a new stake in FibroGen in the 4th quarter valued at $42,000. Squarepoint Ops LLC purchased a new position in FibroGen in the fourth quarter valued at about $205,000. Two Sigma Investments LP lifted its stake in shares of FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 98,888 shares in the last quarter. Finally, Two Sigma Advisers LP boosted its position in shares of FibroGen by 18.3% in the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after buying an additional 135,600 shares during the period. 72.71% of the stock is owned by institutional investors and hedge funds.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.